Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001654954-25-011797
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On October 10, 2025, ENDRA Life Sciences Inc., a Delaware corporation (the “ Company”), entered into a securities purchase agreement (the “ Securities Purchase Agreement”) with certain accredited investors (the “ Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering (the “ Offering”) an aggregate of 744,340 shares (the “ Shares”) of common stock of the Company, par value $0.0001 per share (the “ Common Stock”), and/or prefunded warrants in lieu thereof (the “ Prefunded Warrants”), and warrants (the “ Common Warrants”) to purchase an aggregate of up to 1,488,680 shares of Common Stock at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants were sold at a combined purchase price of $6.57. In accordance with the rules of the Nasdaq Stock Market, a member of the Company’s board of directors who participated in the Offering (the “ Director Participant”) purchased Shares and Common Warrants at a combined purchase price of $7.06 and was issued Common Warrants with an exercise price of $6.81.

The Offering is expected to close on October 15, 2025 (the “ Closing Date”). The gross proceeds of the Offering are expected to be approximately $4.9 million. Lucid Capital Markets, LLC (the “ Placement Agent”) acted as sole placement agent for the Offering.

The Company intends to use the majority of net proceeds from the Offering to establish the Company’s digital asset treasury (“ DAT”) strategy, with a portion for working capital purposes including the pilot validation imaging study of the Company’s TAEUS liver device. Pursuant to the Securities Purchase Agreement, the Company may spend up to $750,000 of Offering proceeds on the pilot validation study and no more than $1 million in the aggregate, including Offering proceeds, on such study.

Each of the Prefunded Warrants is exercisable for one share of Common Stock at the exercise price of $0.0001 per share of Common Stock underlying the Prefunded Warrant (a “ Prefunded Warrant Share”). The Prefunded Warrants are immediately exercisable and may be exercised at any time until all of the Prefunded Warrants issued in the Offering are exercised in full. Each of the Common Warrants is exercisable